B2M and neoplasm: Although we could not confirm whether recognition by CTLs is enhanced by the upregulation of HLA-I and B2M, it has been well established that deficient expression of HLA-I components, including B2M, is a key factor contributing to tumor progression and immunotherapy resistance.